Pharmaceutical

AAIC 2024: Eisai presents positive long-term data with Leqembi

Patients treated with Leqembi over three years have demonstrated a slowing of Alzheimer’s disease progression.

Aug 3, 2024 - 04:00
AAIC 2024: Eisai presents positive long-term data with Leqembi
Patients treated with Leqembi over three years have demonstrated a slowing of Alzheimer’s disease progression.
Read the original article

Tags:

Previous Article

AbbVie acquires Cerevel Therapeutics for $8.7bn

Next Article

Agios Fails to Reach Primary Objective in Pediatric Study

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves over-the-counter Narcan. Here’s what it means

FDA approves over-the-counter Narcan. Here’s what it means

Mar 30, 2023

STAT+: Vertex’s closely watched pain relief drug succeeds in late-stage trials — with a catch

STAT+: Vertex’s closely watched pain relief drug succee...

Jan 30, 2024

Opinion: Pulling probiotics from NICUs can put preemies at risk of necrotizing enterocolitis

Opinion: Pulling probiotics from NICUs can put preemies...

Nov 9, 2023